Study identifier:NIS-CGR-CRE-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multi-centre, open label, non-randomised, non interventional, 24 weeks study for the efficacy and safety of rosuvastatin following its administration in real life clinical practice in Greek hypercholesterolaemic patients
hypercholesterolaemia
-
No
-
All
810
Observational
18 Years - 80 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.
Location
Location
Athens, Greece
Location
Rio, Patra, Greece
Location
Alexandroupoli, Greece
Location
Iraklio, Crete, Greece
Location
Larissa, Greece
Location
Thessaloniki, Greece
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.